



Biovacsafe - Newsletter November 2012

Welcome to our first newsletter



Dear Partners,

We are pleased to introduce you to the first e-newsletter of Biomarkers for Enhanced Vaccine Safety – BioVacSafe - project. We are excited to offer the opportunity to update our partners and everyone else who is interested in our activities as our subscriber lists grow via the e-newsletter format.



Please don't hesitate to forward this mail to anyone who could also be interested in reading it. If they want to receive their own e-newsletter in the future they can subscribe on our website via the link below. If you're not interested in receiving our newsletter anymore, you can unsubscribe via the unsubscribe button at the end of this newsletter.

We hope you will enjoy reading our latest news

Best regards,

Prof. David J. Lewis
Project Coordinator & Managing Entity

Dr. Aldo Tagliabue
EFPIA Coordinator

[Subscribe to this newsletter](#)

BioVacSafe project information



BioVacSafe is an Innovative Medicines Initiative 3rd Call project on Immunosafety of Vaccines. The Consortium is co-ordinated by the University of Surrey and will receive over €30 million funding over 5 years from 1st March 2012.

BioVacSafe is a public private consortium of 19 partners involving three of Europe's leading vaccine producing companies, experts from major academic institutions, small and medium-sized enterprises (SMEs) and non-governmental organization (NGO) actors.

BioVacSafe aims at establishing tools, methods and guidelines for the evaluation of vaccine reactogenicity and enhancing immunosafety of novel vaccines.

A compact interlocking structure provides efficient and cost-effective goal delivery, while offering the full spectrum of functionality and capacity to match the needs for predictive biomarkers and models of inflammation/autoimmunity and clinical events classification.

BioVacSafe partners have a unique opportunity to tackle the urgent need to establish new ways of collaboration among industry, academia, biotech companies, regulators and patients' organizations to promote and support R&D for safer vaccines.

The list of research partners and more information can be found on the website: www.biovacsafe.eu

BioVacSafe leaflet

BioVacSafe leaflet has been developed to broadly communicate the BioVacSafe activities and objectives.

[Here you can find the PDF of the leaflet](#)

Upcoming events:

BioVacSafe CyTof demonstration

The 13th of December 2012 a BioVacSafe CyTof demonstration (mini-workshop/discussion on the mass cytometry) will be organized at the Commissariat à l'énergie atomique et aux énergies alternatives (CEA) in Fontenay aux Roses, France.

The planned program can be found [here](#).

Participants must fill a [form](#) to send back to Antonio Cosma (antonio.cosma@cea.fr).

BioVacSafe annual meeting

Next BioVacSafe annual meeting will be organized only for the partners of the project to present the results of the first year of research.

It will take place in Berlin 21/03/2013 - 22/03/2013

Conference venue: Catholic Academy - <http://www.hotel-aquino.de/>

Hotel: Hotel Melia - <http://www.meliaberlin.com/en/index.htm>

News:

University of Surrey to Open School of Veterinary Medicine on October 25th 2012

The University of Surrey, Guildford, UK announced its plans to open a new School of Veterinary Medicine. The University already has joint teaching arrangements with the Veterinary Laboratory Agency, and the Institute of Animal Health, Surrey to deliver Masters programmes in Veterinary Microbiology and Immunology. The Veterinary Medicine School will be delivered in collaboration with regional veterinary research institutes, local veterinary surgeries and global partners, with the ambition of training the veterinary leaders of the future. Located on the Manor Park side of the campus, adjacent to the Surrey Research Park housing many SMEs, and set in an area of rolling Surrey countryside, the school will take its first cohort of students on the veterinary medicine degree programme in autumn 2014. For further details see <http://www.surrey.ac.uk/vet>

Master Course in Vaccinology and Pharmaceutical Clinical Development

Novartis Vaccines Institute for Global Health (NVGH) organizes, together with University of Siena and Novartis Vaccines Academy, the 3rd Master in Vaccinology and Pharmaceutical Clinical Development in Siena Italy. Fellowships are made available by Advanced Immunization Technologies Project to trainees from EU-based institutions and non-EU institutions that are involved in EC-funded projects like BioVacSafe. Application deadline: February 5th, 2013. More information can be found here: [Master Program in Vaccinology and Pharmaceutical Clinical](#)

Biovacsafe contacts:

info@biovacsafe.eu - <http://www.biovacsafe.eu> - [Facebook](#) - [Twitter](#) - [Linkedin](#)

This project is supported by the grant n° 115308 from the Innovative Medicines Initiative JU, a joint undertaking between the European Union and the EFPIA companies' in kind contribution.

